Literature DB >> 2940303

Teicoplanin compared with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus epidermidis.

D W Galetto, J A Boscia, W D Kobasa, D Kaye.   

Abstract

This study compared teicoplanin with vancomycin without and with gentamicin and/or rifampin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus epidermidis. In rabbits treated for three days and killed 12 hr after the last doses of antimicrobial agents, no significant difference in reducing bacterial titers of vegetations was detected between vancomycin and teicoplanin without and with gentamicin and/or rifampin. Addition of gentamicin and/or rifampin to vancomycin or teicoplanin significantly reduced bacterial titers of vegetations compared with vancomycin or teicoplanin alone. Addition of rifampin alone or gentamicin plus rifampin was significantly more effective than addition of gentamicin alone. In rabbits treated for three days and killed seven days after the last doses of antimicrobial agents, no significant difference in sterilizing vegetations was detected between vancomycin and teicoplanin with gentamicin and/or rifampin. However, there was a trend (probably due to the longer elimination half-life of teicoplanin in serum) that clearly favored teicoplanin over vancomycin. Teicoplanin plus rifampin without or with gentamicin is at least as effective as vancomycin plus rifampin without or with gentamicin for treatment of experimental endocarditis due to methicillin-resistant S. epidermidis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2940303     DOI: 10.1093/infdis/154.1.69

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

Review 1.  In vivo antibiotic synergism: contribution of animal models.

Authors:  B Fantin; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

2.  Pharmacokinetics of teicoplanin in critically ill patients with various degrees of renal impairment.

Authors:  Y Domart; C Pierre; B Clair; J J Garaud; B Regnier; C Gibert
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

3.  Activities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics.

Authors:  V Zarrouk; B Bozdogan; R Leclercq; L Garry; C Feger; C Carbon; B Fantin
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

Review 4.  Laboratory, clinical, and epidemiological aspects of coagulase-negative staphylococci.

Authors:  M A Pfaller; L A Herwaldt
Journal:  Clin Microbiol Rev       Date:  1988-07       Impact factor: 26.132

Review 5.  Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  D M Campoli-Richards; R N Brogden; D Faulds
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

6.  Ciprofloxacin therapy of experimental endocarditis caused by methicillin-resistant Staphylococcus epidermidis.

Authors:  M S Rouse; R M Wilcox; N K Henry; J M Steckelberg; W R Wilson
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

7.  Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis.

Authors:  B J McGrath; S L Kang; G W Kaatz; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

8.  Teicoplanin alone or combined with rifampin compared with vancomycin for prophylaxis and treatment of experimental foreign body infection by methicillin-resistant Staphylococcus aureus.

Authors:  H J Schaad; C Chuard; P Vaudaux; F A Waldvogel; D P Lew
Journal:  Antimicrob Agents Chemother       Date:  1994-08       Impact factor: 5.191

9.  Teicoplanin pharmacokinetics in intravenous drug abusers being treated for bacterial endocarditis.

Authors:  M J Rybak; S A Lerner; D P Levine; L M Albrecht; P L McNeil; G A Thompson; M T Kenny; L Yuh
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

10.  Teicoplanin in the treatment of gram-positive-bacterial endocarditis.

Authors:  P Martino; M Venditti; A Micozzi; C Brandimarte; G Gentile; C Santini; P Serra
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.